Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML
Status:
Recruiting
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of bosutinib when given together
with inotuzumab ozogamicin and to see how well it works in treating patients with acute
lymphoblastic leukemia or chronic myeloid leukemia that has come back or does not respond to
treatment. Bosutinib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to
a toxic substance and may help find cancer cells that express CD22 and kill them without
harming normal cells. Giving bosutinib together with inotuzumab ozogamicin may be a better
treatment for acute lymphoblastic leukemia or chronic myeloid leukemia.